Status:
UNKNOWN
Efficacy and Safety of Latanoprost/Timolol for Primary Open Angle Glaucoma
Lead Sponsor:
Universiti Kebangsaan Malaysia Medical Centre
Conditions:
Primary Open Angle Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Intraocular pressure (IOP) is the most important modifiable risk factor to prevent and delay progression of glaucoma. IOP reduction has been proven to delay the onset and progression of glaucoma, and ...
Eligibility Criteria
Inclusion
- Age 18 and above
- Able to provide informed consent
- Diagnosed as having unilateral or bilateral, mild to moderate POAG
- The POAG treated with only two antiglaucoma
Exclusion
- Advanced POAG
- Patient with contraindication for topical use of a-blocker and prostaglandin analogue
- Patient with contraindication for systemic use of a-blocker
- Patient on systemic use of a-blocker such as metoprolol, propranolol, atenolol
- History of orbital or ocular trauma.
- History of cataract surgery less than 6 months.
- History of previous ocular surgery; e.g. vitreoretinal surgery, corneal transplantation or glaucoma surgery
- Any active eye infections or corneal ulceration.
- Patient with ocular surface disease
- Other ocular disease that might interfere with IOP measurements or result
- Precious eye i.e patient with only one good eye
- Contact lens is not allowed within 1 week before the start of study and during the study
Key Trial Info
Start Date :
January 2 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04098861
Start Date
January 2 2019
End Date
December 1 2020
Last Update
September 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universiti Kebangsaan Malaysia Medical Centre
Cheras, Kuala Lumpur, Malaysia, 56000